Publications & Posters

Publications & Posters

Bioanalysis | May 10, 2017
Ligand-binding techniques such as immunoassays, the reference for clinical diagnosis, offer a wide range of innovative approaches based on signal DNA amplification, nanotechnologies or digital assays, which result in technologies with sensitivities more than 1000-times that of formats used 20 years…
Genetic Engineering & Biotechnology News| February 15, 2017
Tumor biomarkers act as important contextual cues or signals of cancer status.
Journal of Urology | February 2016
In this study we evaluate an ultrasensitive prostate specific antigen assay in patients with prostate cancer after radical prostatectomy to predict long-term biochemical recurrence-free survival.
Analytical Chemistry | February 2, 2016
The cell is the basic unit of biology and protein expression drives cellular function. Tracking protein expression in single cells enables the study of cellular pathways and behavior, but requires methodologies sensitive enough to detect low numbers of protein molecules with a wide dynamic range to…
Scientific Reports | June 8, 2015
Current technologies for cancer screening and detection typically rely on imaging techniques or blood tests that are not accurate or sensitive enough to definitively diagnose cancer at its earliest stages or predict biologic outcomes. By utilizing Single Molecule Arrays (SiMoA), an ultra-sensitive…
2013 Society for Laboratory Automation & Screening Annual Meeting, Orlando, FL
Ubiquitination is a post-translational modification process which involves the attachment of ubiquitin(Ub) to lysine residues on either substrate proteins or itself resulting in protein monoubiquitination or polyubiquitination.
Clinical Chemistry | October 13, 2011
Measurement of prostate-specific antigen (PSA) in prostate cancer patients following radical prostatectomy (RP) has been hindered by the limit of quantification of available assays. We developed an investigational digital immunoassay with a limit of quantification 2 logs lower than current…
2011 AACR, Molecular Diagnostics in Cancer Therapeutic Development, Denver, CO
David Wilson1, David Duffy1, David Rissin1, Cheuk Kan1, Todd Campbell1, Stuart Howes1, David Fournier1, Tomasz Piech1, Gail Provuncher1, Purvish Patel1, Evan Ferrell1, Andrew Rivnak1, Jeff Randall1, Linan Song1, David Walt2.1Quanterix Corporation, Cambridge, MA, 2Tufts University, Boston, MA.